Staphylococcus aureus, methicillin resistant (2018 Data)
Antibiotic |
% Susceptible |
Antibiotic |
% Susceptible |
|
Ampicillin | 0 |
Imipenem | - |
|
Azithromycin | - |
Levofloxacin | 20 |
|
Aztreonam | - |
Meropenem | - |
|
Cefazolin | 0 |
Moxifloxacin | 81
|
|
Cefepime | - |
Nitrofurantoin | 99&
|
|
Ceftazidime | - |
Oxacillin/Naf | 0 |
|
Ceftriaxone | 0 |
Penicillin | 0 |
|
Cefuroxime | - |
Piperacillin | -
|
|
Ciprofloxacin | 18 |
Piperacillin/tazo | - |
|
Clarithromycin | - |
Ticarcillin/Clav | - |
|
Clindamycin | 86 |
Tobramycin | - |
|
Doxycycline | 94 |
TMP/SMX | 100 |
|
Erythromycin | 8 |
Unasyn/Aug | 0 |
|
Gentamicin | - |
Vancomycin | 100 |
|
Number of isolates tested: 775
Comments: 38% of Staphylococcus aureus isolates in 2018 were methicillin resistant (may include duplicates).
For historical susceptibility data click here
Numeric data represent local susceptibility data.
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections
(+) = usually effective or >60% susceptible; (+/-) = clinical trials lacking or 30-60% susceptible; (-) = not effective clinically or <30% susceptible - Adapted with permission from The Sanford Guide to Antimicrobial Therapy
(*) Local (non-Sanford Guide) opinion
(S) = synergistic with penicillin/ampicillin;
(&) nitrofurantoin only useful for lower tract urinary tract infections